Pharmaceutical composition for treating kidney cancer and application thereof
US12156861B2 · kind B2 · utility
0Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 31, 2019 |
| Grant date | Dec 3, 2024 |
| Priority date | — |
| Expiry date | Apr 2, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition contains chlorogenic acid and coumaroyl quinic acid. The combined use of chlorogenic acid and coumaroyl quinic acid at a certain ratio can generate a synergistic enhancing effect to effectively inhibit the growth of human kidney cancer cell strain A479, rat kidney cell strain RuCa, and rat transplanted tumor RuCa, providing a novel choice for clinical treatment of kidney cancer and having good market application prospects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.